Record Information |
---|
Version | 2.0 |
---|
Created at | 2024-09-10 19:46:29 UTC |
---|
Updated at | 2024-09-10 19:46:29 UTC |
---|
NP-MRD ID | NP0334743 |
---|
Secondary Accession Numbers | None |
---|
Natural Product Identification |
---|
Common Name | Testosterone enanthate |
---|
Description | Testosterone enanthate, also known as delatestryl or malogen l.A., Belongs to the class of organic compounds known as steroid esters. Steroid esters are compounds containing a steroid moiety which bears a carboxylic acid ester group. Testosterone enanthate can also be converted to estradiol by aromatase, which may lead to gynecomastia in males. It is or has been marketed under a variety of other brand names as well, including, among others:Andro LAAndropositoryDepandroDurathateEveroneTestostrovalTestrinTestro LAXyostedTestosterone enanthate is available in the United States and widely elsewhere throughout the world. Testosterone enanthate is a drug. Testosterone enanthate is a very hydrophobic molecule, practically insoluble (in water), and relatively neutral. Testosterone enanthate was first documented in 1985 (PMID: 4028529). Side effects of testosterone enanthate include symptoms of masculinization like acne, increased hair growth, voice changes, and increased sexual desire (PMID: 16185098) (PMID: 15329035) (PMID: 17530941) (PMID: 17484401) (PMID: 12792150). |
---|
Structure | [H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1 |
---|
Synonyms | Value | Source |
---|
17-((1-Oxoheptyl)oxy)androst-4-en-3-one | ChEBI | 17-Hydroxyandrost-4-en-3-one, 17-heptanoate | ChEBI | 17beta-Hydroxyandrost-4-en-3-one heptanoate | ChEBI | Testosterone 17-enanthate | ChEBI | Testosterone heptanoate | ChEBI | Delatestryl | Kegg | 17-Hydroxyandrost-4-en-3-one, 17-heptanoic acid | Generator | 17b-Hydroxyandrost-4-en-3-one heptanoate | Generator | 17b-Hydroxyandrost-4-en-3-one heptanoic acid | Generator | 17beta-Hydroxyandrost-4-en-3-one heptanoic acid | Generator | 17Β-hydroxyandrost-4-en-3-one heptanoate | Generator | 17Β-hydroxyandrost-4-en-3-one heptanoic acid | Generator | Testosterone 17-enanthic acid | Generator | Testosterone heptanoic acid | Generator | Testosterone enanthic acid | Generator | 17beta-Enanthoxyandrost-4-en-3-one | HMDB | 17beta-Hydroxyandrost-4-en-3-one enanthate | HMDB | 4-Androsten-17beta-ol-3-one 17-enanthate | HMDB | 4-Androsten-3-one 17beta-enanthate | HMDB | Androgyn l.a. | HMDB | Andropository | HMDB | Androtardyl | HMDB | Atlatest | HMDB | DEA no. 4000 | HMDB | Delatest | HMDB | DePatestrye | HMDB | Depo-testro med | HMDB | Ditate | HMDB | Durathate | HMDB | Everone | HMDB | Exten test | HMDB | Malogen l.a. | HMDB | Malogen l.a.200 | HMDB | Orquisteron-e | HMDB | Primotestone | HMDB | Reposo TMD | HMDB | Testanthate | HMDB | Testate | HMDB | Testenate | HMDB | Testinon | HMDB | Testoenant | HMDB | Testonenant | HMDB | Testosterone 17beta-heptanoate | HMDB | Testosterone 17beta-heptanoic acid | HMDB | Testosterone enantate | HMDB | Testosterone heptoate | HMDB | Testosterone heptoic acid | HMDB | Testosterone heptylate | HMDB | Testosterone oenanthate | HMDB | Testostroval | HMDB | BTG Brand OF testosterone enanthate | HMDB | Jenapharm brand OF testosterone enanthate | HMDB | Rotexmedica brand OF testosterone enanthate | HMDB | Testosteron-depot jenapharm | HMDB | Pasadena brand OF testosterone enanthate | HMDB | Primoteston depot | HMDB | Rugby brand OF testosterone enanthate | HMDB | Testosteron depot-rotexmedica | HMDB | Testosteron-depot eifelfango | HMDB | Testrin p.a. | HMDB | Roberts brand OF testosterone enanthate | HMDB | Eifelfango brand OF testosterone enanthate | HMDB | Schering brand OF testosterone enanthate | HMDB | Theramed brand OF testosterone enanthate | HMDB | Theramex | HMDB |
|
---|
Chemical Formula | C26H40O3 |
---|
Average Mass | 400.5940 Da |
---|
Monoisotopic Mass | 400.29775 Da |
---|
IUPAC Name | (1S,2R,10R,11S,14S,15S)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadec-6-en-14-yl heptanoate |
---|
Traditional Name | everone |
---|
CAS Registry Number | Not Available |
---|
SMILES | [H][C@@]12CC[C@H](OC(=O)CCCCCC)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C |
---|
InChI Identifier | InChI=1S/C26H40O3/c1-4-5-6-7-8-24(28)29-23-12-11-21-20-10-9-18-17-19(27)13-15-25(18,2)22(20)14-16-26(21,23)3/h17,20-23H,4-16H2,1-3H3/t20-,21-,22-,23-,25-,26-/m0/s1 |
---|
InChI Key | VOCBWIIFXDYGNZ-IXKNJLPQSA-N |
---|
Experimental Spectra |
---|
|
| Not Available | Predicted Spectra |
---|
|
| Not Available | Chemical Shift Submissions |
---|
|
| Not Available | Species |
---|
Species of Origin | Not Available |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as steroid esters. Steroid esters are compounds containing a steroid moiety which bears a carboxylic acid ester group. |
---|
Kingdom | Organic compounds |
---|
Super Class | Lipids and lipid-like molecules |
---|
Class | Steroids and steroid derivatives |
---|
Sub Class | Steroid esters |
---|
Direct Parent | Steroid esters |
---|
Alternative Parents | |
---|
Substituents | - Steroid ester
- Androgen-skeleton
- Androstane-skeleton
- 3-oxosteroid
- 3-oxo-delta-4-steroid
- Oxosteroid
- Delta-4-steroid
- Cyclohexenone
- Ketone
- Carboxylic acid ester
- Cyclic ketone
- Monocarboxylic acid or derivatives
- Carboxylic acid derivative
- Organooxygen compound
- Carbonyl group
- Organic oxide
- Organic oxygen compound
- Hydrocarbon derivative
- Aliphatic homopolycyclic compound
|
---|
Molecular Framework | Aliphatic homopolycyclic compounds |
---|
External Descriptors | |
---|
Physical Properties |
---|
State | Not Available |
---|
Experimental Properties | Property | Value | Reference |
---|
Melting Point | Not Available | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | Not Available | Not Available |
|
---|
Predicted Properties | |
---|
General References | - Darby E, Anawalt BD: Male hypogonadism : an update on diagnosis and treatment. Treat Endocrinol. 2005;4(5):293-309. doi: 10.2165/00024677-200504050-00003. [PubMed:16185098 ]
- Gooren LJ, Bunck MC: Androgen replacement therapy: present and future. Drugs. 2004;64(17):1861-91. doi: 10.2165/00003495-200464170-00002. [PubMed:15329035 ]
- Rogerson S, Weatherby RP, Deakin GB, Meir RA, Coutts RA, Zhou S, Marshall-Gradisnik SM: The effect of short-term use of testosterone enanthate on muscular strength and power in healthy young men. J Strength Cond Res. 2007 May;21(2):354-61. doi: 10.1519/R-18385.1. [PubMed:17530941 ]
- Giuberti A, Manganini V, Picozzi SC, Vigano P, Strada GR: Complete genital prosthetization in patients treated with bilateral orchiectomy for metachronous testicular cancer. Arch Ital Urol Androl. 2007 Mar;79(1):26-9. [PubMed:17484401 ]
- Schustack A, Meshiaj D, Waiss Z, Gotloib L: Intramuscular iron replenishment and replacement combined with testosterone enanthate in maintenance hemodialysis anemia: a follow-up of up to 8 years on 16 patients. Clin Nephrol. 1985 Jun;23(6):303-6. [PubMed:4028529 ]
- Schubert M, Bullmann C, Minnemann T, Reiners C, Krone W, Jockenhovel F: Osteoporosis in male hypogonadism: responses to androgen substitution differ among men with primary and secondary hypogonadism. Horm Res. 2003;60(1):21-8. doi: 10.1159/000070823. [PubMed:12792150 ]
|
---|